Caplacizumab

Caplacizumab
Monoclonal antibody
Type	Single domain antibody
Source	Humanized
Target	von Willebrand factor (VWF)
Clinical data
Trade names	Cablivi
Other names	ALX-0081, caplacizumab-yhdp
AHFS/Drugs.com	Monograph
MedlinePlus	a619030
License data	US DailyMed: Caplacizumab;
Pregnancy; category	AU: B1; ;
Routes of; administration	Intravenous, subcutaneous
ATC code	B01AX07 (WHO) ;
Legal status
Legal status	AU: S4 (Prescription only); CA: ℞-only / Schedule D; UK: POM (Prescription only); US: ℞-only; EU: Rx-only;
Identifiers
CAS Number	915810-67-2;
DrugBank	DB06081;
ChemSpider	none;
UNII	2R27AB6766;
KEGG	D11160;
Chemical and physical data
Formula	C1213H1891N357O380S10
Molar mass	27876.19 g·mol−1

Caplacizumab, sold under the brand name Cablivi, is a monoclonal antibody used for the treatment of thrombotic thrombocytopenic purpura. It is a von Willebrand factor-directed antibody fragment. It is given via intravenous injection followed by subcutaneous injection. Caplacizumab was developed by Ablynx NV.

Caplacizumab was authorized for medical use in the European Union in August 2018, and approved for medical use in the United States in February 2019. The US Food and Drug Administration considers it to be a first-in-class medication.